Collectively, these observations indicated that the expression of CMTM6 is elevated in NSCLC, and the level of its expression is inversely correlated with the prognosis of NSCLC patients, as well as with colocalization of EGFR in recycling endosomes in NSCLC tumor tissues, suggesting that CMTM6 is a potential therapeutic target for the treatment of NSCLC. The gene discussed is EGFR; the disease is neoplasm.